CRISPR booked revenue of just under $36 million. On the bottom line, CRISPR flipped to a generally accepted accounting ...

Researchers have been "making great inroads" in precision medicine, and a 15 percent cap on indirect costs could quash the momentum, experts worry.

TD Cowen has upgraded CRISPR Therapeutics (CRSP) to hold from sell, stating it now sees less downside to the stock. Read more ...

CRISPR Therapeutics (NASDAQ:CRSP) received an upgrade in its stock rating by analysts at TD Cowen, changing from Sell to Hold, while maintaining a price target of $35.00. The revision in the rating ...

TD Cowen upgraded Crispr Therapeutics (CRSP) to Hold from Sell with an unchanged price target of $35. The firm continues to be cautious on the ...

Ongoing launch of CASGEVY ® continues to gain momentum; new cell patient collection initiations expected to significantly grow in 2025- -More than 50 authorized treatment centers (ATCs) activated ...

Vertex has entered a reimbursement agreement with NHS England enabling eligible SCD patients to access Casgevy in the public ...

For Vertex these days, it’s all about the launches of three new products—sickle cell disease gene therapy Casgevy, the ...

The company posted quarterly adjusted earnings of $3.48 per share which missed the analyst consensus estimate of $4.03 per ...

Vertex Pharmaceuticals is working toward making its recently approved non-opioid pain medicine Journavx not only broadly ...

The cystic fibrosis treatment leader exceeded revenue expectations, but missed slightly on earnings per share.

Vertex Pharmaceuticals forecast annual revenue largely above Wall Street estimates on Monday, banking on robust sales of its ...